期刊文献+

142例心房颤动住院患者华法林使用情况的回顾性分析 被引量:5

暂未订购
导出
摘要 目的回顾分析心房颤动住院患者华法林抗凝情况,初步探讨基层医院心房颤动患者的华法林治疗现状。方法选择2006年—2007年住院的心房颤动患者142例,全面收集患者血栓栓塞的高危因素、抗凝禁忌症,华法林的用法、用量,以及未用华法林的原因等。结果房颤患者总体接受抗栓治疗(华法林或阿司匹林)者85.28%,其中华法林治疗61.97%,<65岁组华法林治疗66.19%,65岁~75岁组华法林治疗71.69%,<75岁组华法林治疗仅16.67%;高危组华法林治疗71.3%,中危组华法林治疗46.7%,低危组华法林治疗为零。结论住院以房颤动患者总体接受华法林抗凝治疗的情况较好,但>75岁高、中危的老年房颤患者抗凝治疗不足,加强医生对华法林抗凝的认识以及采用更方便安全有效的抗凝新药可能会进一步提高老年患者的抗凝治疗。
出处 《中西医结合心脑血管病杂志》 2008年第10期1213-1214,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献7

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1408
  • 2许俊堂.非瓣膜病性房颤的抗栓疗法[J].中国医刊,2006,41(9):44-47. 被引量:2
  • 3Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population - based cohort. The Framingham Heart Study[J]. JAMA,1994,271:840-844.
  • 4Fuster V, Ryden LE, Cannom S, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation [J]. Circulation, 2006,114 : e257 - e354.
  • 5Joffet IV,Goldhaber SZ. Effectiveness and safety of long -term an- ticoagulation of patients 90 years of age with atrial fibrillation[J].Am J Cardiol,2002,90(12) :1397 - 1398.
  • 6York M, Agarwal A,Ezekowitz M. Physicians attitudes and the use of oral anticoagulants:Surveying the present and envisioning future [J].J Thromb Thrombolysis, 2003,16 : 33 - 37.
  • 7Erlksson BI, Borris LC, Dahl OE, etal. A once-daily, oral, direct factor Xainhibitor, rivaroxaban (BAY 59 - 7939), for thromboprophylaxis after total hip replacement[J]. Circulation, 2006, 114:2374 - 2381.

二级参考文献1

共引文献1408

同被引文献47

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1408
  • 2刘罗薇,刘小军.出院患者电话随访中出现的问题分析及对策[J].护理管理杂志,2005,5(7):18-19. 被引量:84
  • 3万昕红,张麟,那开宪,杨新春.专人负责的随访门诊对持续性房颤病人华法林抗凝治疗疗效的影响[J].中国医药导刊,2006,8(3):190-192. 被引量:8
  • 4心房颤动抗栓研究协作组,胡大一,孙艺红,张鹤萍,姜立清.华法林对非瓣膜病心房颤动抗栓的安全性和有效性研究[J].中华内科杂志,2006,45(10):800-803. 被引量:64
  • 5Carom A J, Kirchhof P, Lip GY,et al. Guidelines for the management of atrial fibrillation : The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology ( ESC ) [J]. Eur Heart J, 2010,31 ( 1 ) :2369.
  • 6St - Louis L, Robichaud - Ekatrand S. Knowledge level and coping strategies according to coagulation levels in older persons with atrial fibrillation [J]. Nurs Health Sci,2003,5 ( 1 ) :67 - 75.
  • 7Lin LJ, Cheng MH, Lee CH, et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation: A nation- wide descriptive study in Taiwan [ J ]. Clin Ther, 2008,30 ( 9 ) : 1726 - 1736.
  • 8Jackson SL, Peterson GM,Vial JH. A community -based educational intervention to improve antithrombotic drug use in atrial fibrillation [J]. Ann Pharmacother,2004,38 ( 11 ) : 1794 - 1799.
  • 9Clacs N, Buntinx F, Vijgen J,et al. The belgian improvement study on oral anticoagulation therapy: A randomized clinical trial [ J ]. Eur Heart J,2005,26(20) :2159 -2165.
  • 10Witt DM, Sadler MA, Shanahan RL,et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy [J]. Chest,2005,127 ( 5 ) : 1515 - 1522.

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部